Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Moodys
Fuji
Boehringer Ingelheim
Cipla
Merck
Daiichi Sankyo
AstraZeneca
Medtronic

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDROCHLOROTHIAZIDE; TELMISARTAN

« Back to Dashboard

Clinical Trials for Hydrochlorothiazide; Telmisartan

Trial ID Title Status Sponsor Phase Summary
NCT00133185 A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to M Completed Boehringer Ingelheim Phase 3 The primary objective of this trial is to compare the efficacy and safety of telmisartan 40 mg/hydrochlorothiazide 12.5mg (Micardis Plus) with that of losartan 50 mg/hydrochlorothiazide 12.5 mg, a reference AIIA combined with diuretic, in Taiwanese patients with mild to moderate hypertension.
NCT00144222 Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy Completed Boehringer Ingelheim Phase 3 The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) 40 mg in patients with essential hypertension who fail to respond adequately to telmisartan monotherapy.
NCT00146341 Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg Completed Boehringer Ingelheim Phase 3 To demonstrate that a fixed dose combination of telmisartan 80 mg plus HCTZ 12.5 mg is superior to telmisartan 80 mg alone in patients, who fail to respond adequately to telmisartan 80 mg monotherapy, in lowering seated trough diastolic blood pressure after eight weeks of treatment.
NCT00153049 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension Completed Boehringer Ingelheim Phase 2 1. To investigate the dose response of the combination therapy, Telmisartan and Hydrochlorothiazide for the Japanese patients with Essential Hypertension. 2. To compare this dose response with that in the US study.
NCT00168779 Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension Completed Boehringer Ingelheim Phase 4 The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg / hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Hydrochlorothiazide; Telmisartan

Condition Name

Condition Name for Hydrochlorothiazide; Telmisartan
Intervention Trials
Hypertension 33
Healthy 9
Essential Hypertension 3
Albuminuria 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Hydrochlorothiazide; Telmisartan
Intervention Trials
Hypertension 32
Diabetes Mellitus 2
Diabetes Mellitus, Type 2 1
Albuminuria 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Hydrochlorothiazide; Telmisartan

Trials by Country

Trials by Country for Hydrochlorothiazide; Telmisartan
Location Trials
United States 132
Japan 10
Canada 9
Korea, Republic of 8
China 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Hydrochlorothiazide; Telmisartan
Location Trials
Ohio 5
Missouri 5
Florida 5
California 5
Alabama 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Hydrochlorothiazide; Telmisartan

Clinical Trial Phase

Clinical Trial Phase for Hydrochlorothiazide; Telmisartan
Clinical Trial Phase Trials
Phase 4 12
Phase 3 18
Phase 2 1
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Hydrochlorothiazide; Telmisartan
Clinical Trial Phase Trials
Completed 42
Active, not recruiting 1
Unknown status 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Hydrochlorothiazide; Telmisartan

Sponsor Name

Sponsor Name for Hydrochlorothiazide; Telmisartan
Sponsor Trials
Boehringer Ingelheim 35
IlDong Pharmaceutical Co Ltd 3
Institut de Recherches Cliniques de Montreal 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Hydrochlorothiazide; Telmisartan
Sponsor Trials
Industry 39
Other 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Baxter
Covington
Queensland Health
US Army
Healthtrust
AstraZeneca
Express Scripts
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.